小分子藥物開發產業聯盟研討會

**講題**

**「台灣生技醫藥公司連結國際市場資源—**

**併購及融資管道實務」講習會**

**「M&A, IPO in US & Hongkong experiences」**

**顧靜玉律師Portia Ku, Partner**

**O’Melveny & Myers**

|  |
| --- |
|  |

生技醫藥產業由於研發時程較長，所須資金龐大，為協助國內生技製藥新創產業了解籌資管道及如何提高成功率，特邀請知名律師事務所O’Melveny & Myers的**顧靜玉律師**為我們分享她20幾年協助各國企業在美國或香港或大陸的IPO經驗，借鏡學習在各階段所需的準備工作及在各國進行時互動的注意事項。

另外，合資、併購、策略聯盟是企業成長重要的策略手段之一，「台灣生醫產業推動方案」亦鼓勵「連結國際市場資源」，發揮台灣特點推動併購及策略聯盟，併購成功與否有賴事前的規劃與事後的整合，顧律師也會帶領我們了解其中的眉角，做為公司發展策略規劃的參考。敬邀各位先進一起來研習與交流！

**指導單位:**經濟部技術處

**主辦單位：**「小分子藥物開發產業聯盟」/工研院生醫所

**時 間：**107年7月10日 (星期­二 9:30 am -13:00 pm)

**地 點：**工業技術研究院 光復院區一館六樓 601室 (新竹市光復路二段 321號，新大樓)

**報名費用：**「小分子藥物開發產業聯盟」會員、醫師、老師及學生免費。其他每位1,000元 (含講義與餐點)。

**議 程：**

|  |  |  |
| --- | --- | --- |
| 時間 | 題目 | 講師 |
| 09：30~09：50 | 報到 |  |
| 09：50~10：00 | 致歡迎詞 | 黃崇雄 副所長 |
| 10：00~12：00(含break) | 「M&A, IPO in US & Hongkong experiences」 | O’Melveny & Myers Portia Ku (顧靜玉律師)Partner |
| 12：00~12：30 | 綜合討論 |  |
|  12：30~13：00  | 午餐 |  |

**報名方法:**

**「小分子藥物開發產業聯盟」會員**

 **林舒蓉小姐 電話:03-5732850 信箱:** **lin0068@itri.org.tw**

**繳費方式：**

□ 劃線即期支票 / 郵政匯票繳款：抬頭為「工業技術研究院」

請寄至：(300)新竹市光復路二段321號19館202室，林舒蓉小姐收，

電話:03-5732850

* 電匯繳款：銀行別：土地銀行工研院分行，帳號：156-005-00002-5，戶名：財團法人工業技術研究院，並於備註欄位說明「參加7/10「小分子藥物開發產業聯盟」研討會」

|  |  |  |  |
| --- | --- | --- | --- |
| **公司名稱：** |  | **統編** |  |
| **姓 名：** |  | **職 稱：** |  | **午餐** |
| **電 話：** |  | **E-mail：** |  | **葷🞏 素🞏** |

**本案聯絡人:**

**工研院生醫所 林慧琪小姐，電話:03-5743977 ， 信箱: huichilin@itri.org.tw**

 **林舒蓉小姐，電話:03-5732850**

**講師簡歷:**

**O’Melveny & Myers**

**Portia Ku (顧靜玉律師)**

**Partner**

**pku@omm.com**

[https://www.omm.com/professionals/ching-yu-ku/#](https://www.omm.com/professionals/ching-yu-ku/)

**Education:**

Yale University, LL.M.

National Taiwan University, LL.B.

**Bar Admissions**

California

New York

Taiwan

Portia Ku is an accomplished corporate transactional lawyer who specializes in capital markets, mergers and acquisitions, venture capital and private equity financings. Portia’s clients include public and private companies that span a variety of industries, including the technology, life sciences, healthcare, and financial services sectors.

Portia has successfully completed a myriad of deals on behalf of her clients. She applies her expansive technical experience, strategic execution, and dedication to guide clients through highly complex transactions while ultimately helping them achieve their corporate goals.

**IPO Experience (companies):以下列舉生醫產業相關公司案例**

* Represented China Kanghui Holdings康輝控股(中國)公司-骨科醫療器械[生產](https://www.moneydj.com/KMDJ/wiki/WikiViewer.aspx?Title=%u751F%u7522)公司(NYSE: KH) in its US$78.7 million US IPO
* Represented WuXi PharmaTech藥明康德 (NYSE: WX) in its US$212 million **US IPO**
* Represented Mindray Medical International Limited 邁瑞醫療(NYSE: MR) in its US$320 million US IPO
* Represented LifeTech Scientific Corporation先健科技 (8122.HK) in its HK$283 million IPO on the Growth Enterprise Market of the HKEX
* ……..

**Mergers & Acquisitions:**

* Represented **Vivo Capital**, in the consortium’s US$505 million **acquisition of Angiotech Pharmaceuticals, Inc**., a company specializing in the design and manufacturing of high performance surgical knives and wound closure products
* Represented **Pharmaron**, in its definitive agreement to **acquire a majority stake in Shin Nippon Biomedical Laboratories Clinical Pharmacology** Center, Inc. (SNBL CPC)
* Represented Pharmaron, in its definitive agreement with a consortium led by CITIC M&A Fund and Legend Capital, which will invest more than US$280 million in the company
* Represented China Kanghui in its US$816 million acquisition by Medtronic
* Represented LifeTech in a series of strategic investment transactions with Medtronic, including the sale of HK$2.18 billion of convertible notes to Medtronic
* ……….